These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37180591)

  • 1. A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam.
    Van Anglen LJ; Schroeder CP; Couch KA
    Open Forum Infect Dis; 2023 May; 10(5):ofad173. PubMed ID: 37180591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.
    Jorgensen SCJ; Trinh TD; Zasowski EJ; Lagnf AM; Simon SP; Bhatia S; Melvin SM; Steed ME; Finch NA; Morrisette T; Estrada SJ; Rosenberg JR; Davis SL; Rybak MJ
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
    García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva D; Chaves C; Pássaro L; Paixão L; Cantón R;
    Int J Antimicrob Agents; 2020 Mar; 55(3):105887. PubMed ID: 31926283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
    Bassetti M; Castaldo N; Cattelan A; Mussini C; Righi E; Tascini C; Menichetti F; Mastroianni CM; Tumbarello M; Grossi P; Artioli S; Carannante N; Cipriani L; Coletto D; Russo A; Digaetano M; Losito AR; Peghin M; Capone A; Nicolè S; Vena A;
    Int J Antimicrob Agents; 2019 Apr; 53(4):408-415. PubMed ID: 30415002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
    Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
    [No Abstract]   [Full Text] [Related]  

  • 8. Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States 2018-2019.
    Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
    BMC Microbiol; 2021 Mar; 21(1):74. PubMed ID: 33676406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U.S. gram-negative bacterial surveillance isolates (2012-2018).
    Shortridge D; Carvalhaes CG; Streit JM; Flamm RK
    Diagn Microbiol Infect Dis; 2021 May; 100(1):115302. PubMed ID: 33516987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftolozane/tazobactam for difficult-to-treat Gram-negative infections: A real-world tertiary hospital experience.
    Ronda M; Pérez-Recio S; González Laguna M; Tubau Quintano MF; Llop Talaveron J; Soldevila-Boixader L; Carratalà J; Cuervo G; Padullés A
    J Clin Pharm Ther; 2022 Jul; 47(7):932-939. PubMed ID: 35255527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of ceftolozane-tazobactam and comparators against gram-negative bacilli: Results from the study for monitoring antimicrobial resistance trends (SMART - Brazil; 2016-2017).
    Beirão EM; Rodrigues SDS; Andrade TK; Serra FB; Paula MDN; Polis TJB; Gales AC
    Braz J Infect Dis; 2020; 24(4):310-321. PubMed ID: 32663440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry.
    Zhanel GG; Dhami R; Baxter M; Kosar J; Cervera C; Irfan N; Zvonar R; Borgia S; Tessier JF; Dow G; Ariano R; Dube M; Savoie M; Bassetti M; Walkty A; Karlowsky JA
    J Glob Antimicrob Resist; 2021 Jun; 25():346-350. PubMed ID: 33984530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferiority trial.
    Stewart AG; Harris PNA; Chatfield MD; Littleford R; Paterson DL
    Trials; 2021 Apr; 22(1):301. PubMed ID: 33888139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections.
    Puzniak L; Dillon R; Palmer T; Collings H; Enstone A
    Infect Dis Ther; 2021 Sep; 10(3):1227-1252. PubMed ID: 34278551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience With Ceftolozane-Tazobactam for the Treatment of Serious
    Bosaeed M; Ahmad A; Alali A; Mahmoud E; Alswidan L; Alsaedy A; Aljuhani S; Alalwan B; Alshamrani M; Alothman A
    Infect Dis (Auckl); 2020; 13():1178633720905977. PubMed ID: 32110036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world use of ceftolozane/tazobactam: a systematic literature review.
    Puzniak L; Dillon R; Palmer T; Collings H; Enstone A
    Antimicrob Resist Infect Control; 2021 Apr; 10(1):68. PubMed ID: 33832545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018).
    Cantón R; Loza E; Arcay RM; Cercenado E; Castillo FJ; Cisterna R; Gálvez-Benítez L; González Romo F; Hernández-Cabezas A; Rodríguez-Lozano J; Suárez-Barrenechea AI; Tubau F; Díaz-Regañón J; López-Mendoza D;
    Rev Esp Quimioter; 2021 Jun; 34(3):228-237. PubMed ID: 33645948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections.
    Giancola SE; Mahoney MV; Bias TE; Hirsch EB
    Ther Clin Risk Manag; 2016; 12():787-97. PubMed ID: 27279744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
    Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
    Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study.
    García-Fernández S; García-Castillo M; Bou G; Calvo J; Cercenado E; Delgado M; Pitart C; Mulet X; Tormo N; Mendoza DL; Díaz-Regañón J; Cantón R;
    Int J Antimicrob Agents; 2019 May; 53(5):682-688. PubMed ID: 30769199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.